全文获取类型
| 收费全文 | 6433篇 |
| 免费 | 320篇 |
| 国内免费 | 65篇 |
专业分类
| 耳鼻咽喉 | 47篇 |
| 儿科学 | 193篇 |
| 妇产科学 | 143篇 |
| 基础医学 | 645篇 |
| 口腔科学 | 146篇 |
| 临床医学 | 443篇 |
| 内科学 | 1705篇 |
| 皮肤病学 | 127篇 |
| 神经病学 | 384篇 |
| 特种医学 | 381篇 |
| 外科学 | 1147篇 |
| 综合类 | 18篇 |
| 预防医学 | 219篇 |
| 眼科学 | 53篇 |
| 药学 | 297篇 |
| 中国医学 | 8篇 |
| 肿瘤学 | 862篇 |
出版年
| 2024年 | 10篇 |
| 2023年 | 90篇 |
| 2022年 | 128篇 |
| 2021年 | 252篇 |
| 2020年 | 155篇 |
| 2019年 | 219篇 |
| 2018年 | 272篇 |
| 2017年 | 170篇 |
| 2016年 | 195篇 |
| 2015年 | 201篇 |
| 2014年 | 308篇 |
| 2013年 | 358篇 |
| 2012年 | 505篇 |
| 2011年 | 517篇 |
| 2010年 | 283篇 |
| 2009年 | 251篇 |
| 2008年 | 403篇 |
| 2007年 | 384篇 |
| 2006年 | 342篇 |
| 2005年 | 406篇 |
| 2004年 | 339篇 |
| 2003年 | 308篇 |
| 2002年 | 262篇 |
| 2001年 | 36篇 |
| 2000年 | 28篇 |
| 1999年 | 36篇 |
| 1998年 | 64篇 |
| 1997年 | 45篇 |
| 1996年 | 39篇 |
| 1995年 | 33篇 |
| 1994年 | 27篇 |
| 1993年 | 23篇 |
| 1992年 | 12篇 |
| 1991年 | 10篇 |
| 1990年 | 15篇 |
| 1989年 | 12篇 |
| 1988年 | 13篇 |
| 1987年 | 6篇 |
| 1986年 | 12篇 |
| 1985年 | 5篇 |
| 1984年 | 7篇 |
| 1983年 | 3篇 |
| 1982年 | 5篇 |
| 1981年 | 4篇 |
| 1980年 | 6篇 |
| 1977年 | 3篇 |
| 1975年 | 2篇 |
| 1971年 | 2篇 |
| 1965年 | 2篇 |
| 1904年 | 2篇 |
排序方式： 共有6818条查询结果，搜索用时 15 毫秒
51.
Federico Cagnazzo Pierre-Henri Lefevre Daniel Mantilla Aymeric Rouchaud Riccardo Morganti Paolo Perrini Davide Di Carlo Cyril Dargazanli Gregory Gascou Carlos Riquelme Alain Bonafe Vincent Costalat 《Journal of neuroradiology. Journal de neuroradiologie》2019,46(1):9-14
Background and purpose
Placement of flow-diverters across the ostia of major ICA branches carries a risk of arterial occlusion. We determined the rate of occlusion of the supraclinoid ICA branches and the related symptoms, following coverage with flow-diverters.Materials and methods
A systematic search was performed in PubMed, MEDLINE, and EMBASE. We selected studies reporting treatments with flow-diverters in which the device was placed across the ostium of the OphtA, PcomA, or AchorA. Random-effects meta-analysis was used to pool the following outcomes: rate of arterial occlusion, diminished flow, incidence of related symptoms, factors associated with arterial occlusion.Result
Twenty-one studies evaluating 1152 supraclinoid ICA branches were included in the meta-analysis. The incidence of OphtA occlusion and associated symptoms was 5.9% (95 CI%?=?3.1–8.6%) (incidence rate?=?6% per patient-year), and 0.8% (95% CI?=?0.1–1.4%) (incidence rate?=?0.8% per patient-year), respectively. Although asymptomatic in all cases, PcomA showed a higher occlusion rate (20.7%, 95% CI?=?8.9–32.4%) (incidence rate?=?19.5% per patient-year). AchorA was occluded in 1% (95% CI?=?0.3–2.4%) of cases, with approximately 1% (95% CI?=?0.4–2.3%) of transient neurological symptoms (incidence rate?=?0.96% per patient-year). There was a trend toward higher odds of arterial patency among arteries arising from the aneurysm (OR?=?2.94, P?=?0.06). Demographic factors and multiple stents were not associated with higher risk of arterial impairment. Adequate collateral circulation was reported in 94.5% of patients with arterial occlusion.Conclusions
During aneurysm treatment, the ostium of the supraclinoid ICA branches can be covered with flow-diverter devices with low rates of neurological symptoms related to arterial occlusion. 相似文献52.
Andrei Fodor Sara Broggi Elena Incerti Italo Dell’Oca Claudio Fiorino Ana M. Samanes Gajate Marcella Pasetti Mauro G. Cattaneo Paolo Passoni Luigi Gianolli Riccardo Calandrino Maria Picchio Nadia Di Muzio 《Clinical lung cancer》2019,20(1):e29-e38
Introduction
The objective of this study was to present the outcomes of moderately hypofractionated helical intensity-modulated radiation therapy (HT) with/without simultaneous integrated boost (SIB) on fluorodeoxyglucose-positron emission tomography (FDG-PET) positive areas (gross tumor volume [GTV]-PET) for patients with progressive malignant pleural mesothelioma (MPM) after previous treatments.Methods and Materials
From May 2006 to April 2014, 51 patients with a median age of 68.8 years (range, 38.6-82 years) were treated. There were 41 men and 10 women; 43 epithelioid MPM and 8 sarcomatoid, involving the left pleura in 25 patients and the right pleura in 26 patients. The initial stage was: I, 11 patients; II, 14 patients; III, 17 patients; and IV, 9 patients. Chemotherapy was prescribed for 46 patients, for 6 cycles (range, 0-18 cycles). Eighteen patients had pleurectomy/decortication, and 33 had talc pleurodesis. FDG-PET was used for target identification. A median dose of 56 Gy/25 fractions was prescribed to the involved pleura, and SIB to 62.5 Gy to GTV-PET was added in 38 patients.Results
The median survival from diagnosis was 25.8 months (range, 8.4-99.0 months). One patient, treated with SIB, was alive at the October 2017 follow-up. Two cases of grade 5 radiation pneumonitis were registered. A GTV-PET ≤ 205 cc was predictive of late ≥ grade 2 lung toxicity, but also of better survival in stage III and IV disease: 5.9 versus 11.7 months (P = .04). A GTV-PET ≥ 473 cc was predictive of early death (P = .001).Conclusions
Moderately hypofractionated, FDG-PET guided salvage HT in patients with progressive MPM after previous treatments showed acceptable toxicity and outcome results similar to adjuvant radiotherapy after pleurectomy/decortication, suggesting that the delay of radiotherapy is not detrimental to survival, and has the associated benefit of postponing inherent toxicity. 相似文献53.
54.
55.
56.
Alice Bergamini Umberto Leone Roberti Maggiore Simone Ferrero Emanuela Rabaiotti Riccardo Viganò Micaela Petrone 《Expert opinion on investigational drugs》2015,24(3):345-362
Introduction: Pelvic serous carcinomas (PSCs) are a controversial entity, which mostly comprise fallopian tube carcinoma (FTC), primary peritoneal carcinoma (PPC) and serous ovarian carcinoma (OC). Despite incremental attention towards understanding pelvic serous carcinogenesis, the gold standard treatment and survival rates have not substantially changed in these last decades.
Areas covered: This review summarizes and gives a critical overview of the ongoing Phase II trials investigating therapies for PSC.
Expert opinion: Several novel molecules have been developed and are currently under investigation for the treatment of PSC, including FTC, PPC and serous OC. The trend of novel targeted agents is one towards individualized, tailored therapy, based on the molecular and biological differences that characterize tumors that seem similar based solely on histological analysis. The task of developing new molecules is particularly difficult for PSC, given the recurrent development of new patterns of drug resistance. However, even if current research is focused towards identifying the best treatments for each woman with a molecularly defined disease, a deeper knowledge of the molecular biology and genetics underlying FTC and its relation as a precursor of PSC is needed. 相似文献
57.
Ivan Gentile Emanuela Zappulo Antonio Riccardo Buonomo Riccardo Scotto Guglielmo Borgia 《Expert opinion on drug safety》2015,14(10):1631-1646
Introduction: The introduction of direct-acting antiviral (DAA) agents has revolutionized the treatment of hepatitis C virus (HCV) chronic infection. Non-structural 3 protease inhibitors are currently the most numerous class of DAAs on the market.Areas covered: This review mainly focuses on the tolerability and safety profile of asunaprevir (ASV)-containing DAA regimens. ASV is a second-wave protease inhibitor currently in Phase III clinical development in most countries and already available in Japan.Expert opinion: ASV shows potent antiviral effect and clinical efficacy on HCV genotypes 1 and 4. The all-oral combination daclatasvir/ASV reached high eradication rates in HCV genotype 1b and 4 infection, and a lower efficacy in genotype 1a infection. ASV presents a low potential for drug–drug interaction and a good tolerability as part of multiple, including all-oral, regimens. ASV is associated with a transient and usually mild increase in aminotransferase levels in a low percentage of cases. Due to the impaired pharmacokinetic profile observed in advanced liver disease, ASV use in patients with moderate or severe hepatic impairment is not allowed. In conclusion, ASV represents a powerful weapon against HCV infection and has to be considered an optimal option as a component of genotype tailored interferon-free combinations. 相似文献
58.
Bixio Riccardo Bertelle Davide Pistillo Francesca Pedrollo Elisa Carletto Antonio Rossini Maurizio Viapiana Ombretta 《Clinical rheumatology》2022,41(4):1247-1254
Clinical Rheumatology - Myasthenia gravis is an autoimmune disease affecting the neuromuscular junction, often associated with other autoimmune diseases, including rheumatoid arthritis. Patients... 相似文献
59.
